Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report) shares gapped down prior to trading on Tuesday after Royal Bank of Canada lowered their price target on the stock from $17.00 to $15.00. The stock had previously closed at $6.17, but opened at $5.86. Royal Bank of Canada currently has an outperform rating on the stock. Verve Therapeutics shares last traded at $5.93, with a volume of 651,003 shares traded.
VERV has been the topic of a number of other research reports. William Blair reiterated an “outperform” rating on shares of Verve Therapeutics in a research report on Friday, February 21st. HC Wainwright boosted their price objective on shares of Verve Therapeutics from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Finally, Canaccord Genuity Group upped their price objective on shares of Verve Therapeutics from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $25.50.
Read Our Latest Report on Verve Therapeutics
Institutional Trading of Verve Therapeutics
Verve Therapeutics Stock Performance
The stock has a market capitalization of $518.14 million, a P/E ratio of -2.49 and a beta of 1.74. The business has a 50-day moving average price of $6.92 and a 200 day moving average price of $6.04.
Verve Therapeutics (NASDAQ:VERV – Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.14. The company had revenue of $13.08 million for the quarter, compared to the consensus estimate of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. As a group, research analysts forecast that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current fiscal year.
Verve Therapeutics Company Profile
Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.
Further Reading
- Five stocks we like better than Verve Therapeutics
- 3 Healthcare Dividend Stocks to Buy
- GitLab: Get In While It’s Down—Big Rebound Ahead
- There Are Different Types of Stock To Invest In
- Tesla Stock: Finding a Bottom May Take Time
- Stock Dividend Cuts Happen Are You Ready?
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Verve Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verve Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.